{"brief_title": "CPG 7909 in Patients Wih Stage IV Renal Cell Cancer", "brief_summary": "CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be included in the study.", "condition": ["Carcinoma, Renal Cell"], "intervention_type": ["Drug"], "intervention_name": ["CPG 7909"], "description": ["In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks."], "arm_group_label": ["CPG 7909 Injection"], "other_name": ["PF-03512676"], "criteria": "Inclusion Criteria: Stage IV Renal Cell Carcinoma with lung and/or soft tissue metastasis Nephrectomy Measurable disease by RECIST criteria Exclusion Criteria: CNS, bone or Liver metastasis Tumors that are mainly papillary, chromophobe, medullary, collecting duct, or unclassified Prior immunotherapy, including IL-2 or IFN-alpha", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Renal Cell Carcinoma, Phase I, Phase II, Immunotherapy", "mesh_term": ["Carcinoma", "Carcinoma, Renal Cell"], "id": "NCT00043407"}